Patents
Literature
2 results about "Mumpsvax" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mumpsvax is a mumps vaccine made of mumps virus. Mumpsvax is a product of Merck & Co.,Inc. The vaccine is a component of Merck's three-virus MMR vaccine. Mumpsvax is administered by a subcutaneous injection of live virus reconstituted from freeze-dried vaccine. The dosage of the mumps vaccine component in MMR is the same as of Mumpsvax, "Each 0.5 mL dose contains not less than 20,000 TCID₅₀ of mumps virus." The Merck product information recommends MMR as the secondary vaccination treatment with Mumpsvax. Mumpsvax is produced from the Jeryl Lynn strain of mumps virus developed by Maurice Hilleman. When his daughter Jeryl Lynn Hilleman contracted Mumps Dr. Hilleman cultured the vaccine strain from her throat. The mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production.
A kit for detecting the pathogen of turtle mumps disease and its usage method
PendingCN122081455Amild dispersionPromote microsphere enrichmentSilicaMicrobiological testing/measurementDiseaseMicrosphere
This invention provides a kit for detecting the pathogen of turtle mumps disease and its usage method, belonging to the field of biodetection technology. The kit includes a tissue pathogen release buffer, magnetic macroporous SiO2 microspheres, nucleic acid extraction solution, and detection reagents for the turtle mumps disease pathogen. This invention uses the tissue pathogen release buffer to release pathogens from tissues, magnetic macroporous SiO2 microspheres for pathogen enrichment, and nucleic acid extraction reagents to obtain a crude extract that can be directly used for LAMP amplification and qPCR amplification detection.
Owner:SHAANXI NORMAL UNIV
Mumps and measles virus immunogens and their use
ActiveUS12636360B2SsRNA viruses negative-senseAntibody mimetics/scaffoldsMeasles virus IgGChimera Protein
Embodiments of immunogens comprising a recombinant Mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant Measles (MeV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in a subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES